Product News

Share this article:
Watson received FDA approval for a generic version of Plan B, Duramed Pharmaceuticals' emergency contraceptive. Watson's generic is approved for prescription only, in women 17 and younger. Duramed retains OTC exclusivity on the product – indicated for women 18 years and older – until August 24, 2009.

FDA did not approve GlaxoSmithKline's Rexonic (casopitant mesylate), an antiemetic. FDA issued a complete response letter containing questions that “preclude the approval of the application,” according to a GSK statement. “[GSK] is reviewing this letter and will engage FDA to determine appropriate next steps,” the statement said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters